136 related articles for article (PubMed ID: 32642630)
1. A Phase I Study of Ribociclib Plus Everolimus in Patients with Metastatic Pancreatic Adenocarcinoma Refractory to Chemotherapy.
Weinberg BA; Wang H; Witkiewicz AK; Marshall JL; He AR; Vail P; Knudsen ES; Pishvaian MJ
J Pancreat Cancer; 2020; 6(1):45-54. PubMed ID: 32642630
[No Abstract] [Full Text] [Related]
2. Phase I study of ribociclib and everolimus in children with newly diagnosed DIPG and high-grade glioma: A CONNECT pediatric neuro-oncology consortium report.
DeWire M; Lazow M; Campagne O; Leach J; Fuller C; Senthil Kumar S; Stanek J; de Blank P; Hummel TR; Pillay-Smiley N; Salloum R; Stevenson CB; Baxter P; Gass D; Goldman S; Leary SES; Carle A; Mikael L; Crabtree D; Chaney B; Lane A; Drissi R; Stewart CF; Fouladi M
Neurooncol Adv; 2022; 4(1):vdac055. PubMed ID: 35611273
[TBL] [Abstract][Full Text] [Related]
3. A Phase I and Surgical Study of Ribociclib and Everolimus in Children with Recurrent or Refractory Malignant Brain Tumors: A Pediatric Brain Tumor Consortium Study.
DeWire MD; Fuller C; Campagne O; Lin T; Pan H; Young Poussaint T; Baxter PA; Hwang EI; Bukowinski A; Dorris K; Hoffman L; Waanders AJ; Karajannis MA; Stewart CF; Onar-Thomas A; Fouladi M; Dunkel IJ
Clin Cancer Res; 2021 May; 27(9):2442-2451. PubMed ID: 33547201
[TBL] [Abstract][Full Text] [Related]
4. A Phase 0 Trial of Ribociclib in Recurrent Glioblastoma Patients Incorporating a Tumor Pharmacodynamic- and Pharmacokinetic-Guided Expansion Cohort.
Tien AC; Li J; Bao X; Derogatis A; Kim S; Mehta S; Sanai N
Clin Cancer Res; 2019 Oct; 25(19):5777-5786. PubMed ID: 31285369
[TBL] [Abstract][Full Text] [Related]
5. Ribociclib and everolimus in well-differentiated foregut neuroendocrine tumors.
Raj N; Zheng Y; Hauser H; Chou J; Rafailov J; Bou-Ayache J; Sawan P; Chaft J; Chan J; Perez K; Rudin C; Tang L; Reidy-Lagunes D
Endocr Relat Cancer; 2021 Apr; 28(4):237-246. PubMed ID: 33640871
[TBL] [Abstract][Full Text] [Related]
6. SAR-096: Phase II Clinical Trial of Ribociclib in Combination with Everolimus in Advanced Dedifferentiated Liposarcoma (DDL) and Leiomyosarcoma (LMS).
Movva S; Matloob S; Handorf EA; Choy E; Merriam P; Flieder DB; Cai KQ; Zhou Y; Tetzlaff ED; Pagan C; Barker E; Veggeberg R; Zumpano D; Rink L; von Mehren M; George S
Clin Cancer Res; 2024 Jan; 30(2):315-322. PubMed ID: 37967116
[TBL] [Abstract][Full Text] [Related]
7. Ribociclib Plus Trastuzumab in Advanced HER2-Positive Breast Cancer: Results of a Phase 1b/2 Trial.
Goel S; Pernas S; Tan-Wasielewski Z; Barry WT; Bardia A; Rees R; Andrews C; Tahara RK; Trippa L; Mayer EL; Winer EP; Spring LM; Tolaney SM
Clin Breast Cancer; 2019 Dec; 19(6):399-404. PubMed ID: 31235441
[TBL] [Abstract][Full Text] [Related]
8. A Phase I Study of the CDK4/6 Inhibitor Ribociclib (LEE011) in Pediatric Patients with Malignant Rhabdoid Tumors, Neuroblastoma, and Other Solid Tumors.
Geoerger B; Bourdeaut F; DuBois SG; Fischer M; Geller JI; Gottardo NG; Marabelle A; Pearson ADJ; Modak S; Cash T; Robinson GW; Motta M; Matano A; Bhansali SG; Dobson JR; Parasuraman S; Chi SN
Clin Cancer Res; 2017 May; 23(10):2433-2441. PubMed ID: 28432176
[No Abstract] [Full Text] [Related]
9. Everolimus and erlotinib as second- or third-line therapy in patients with advanced non-small-cell lung cancer.
Papadimitrakopoulou VA; Soria JC; Jappe A; Jehl V; Klimovsky J; Johnson BE
J Thorac Oncol; 2012 Oct; 7(10):1594-601. PubMed ID: 22968184
[TBL] [Abstract][Full Text] [Related]
10. Tumor pharmacokinetics and pharmacodynamics of the CDK4/6 inhibitor ribociclib in patients with recurrent glioblastoma.
Miller TW; Traphagen NA; Li J; Lewis LD; Lopes B; Asthagiri A; Loomba J; De Jong J; Schiff D; Patel SH; Purow BW; Fadul CE
J Neurooncol; 2019 Sep; 144(3):563-572. PubMed ID: 31399936
[TBL] [Abstract][Full Text] [Related]
11. Phase II Study of BEZ235 versus Everolimus in Patients with Mammalian Target of Rapamycin Inhibitor-Naïve Advanced Pancreatic Neuroendocrine Tumors.
Salazar R; Garcia-Carbonero R; Libutti SK; Hendifar AE; Custodio A; Guimbaud R; Lombard-Bohas C; Ricci S; Klümpen HJ; Capdevila J; Reed N; Walenkamp A; Grande E; Safina S; Meyer T; Kong O; Salomon H; Tavorath R; Yao JC
Oncologist; 2018 Jul; 23(7):766-e90. PubMed ID: 29242283
[TBL] [Abstract][Full Text] [Related]
12. Phase 1 Study Evaluating the Association of the Cyclin-Dependent Kinase 4/6 Inhibitor Ribociclib and Cetuximab in Recurrent/Metastatic p16-Negative Squamous Cell Carcinoma of the Head and Neck.
Seront E; Schmitz S; Papier M; van Maanen A; Henry S; Lonchay C; Rottey S; van Caloen G; Machiels JP
Front Oncol; 2019; 9():155. PubMed ID: 30941307
[No Abstract] [Full Text] [Related]
13. Phase I Trial of Everolimus and Capecitabine in Metastatic HER2
Vidal GA; Chen M; Sheth S; Svahn T; Guardino E
Clin Breast Cancer; 2017 Oct; 17(6):418-426. PubMed ID: 28385537
[TBL] [Abstract][Full Text] [Related]
14. Phase II study of capecitabine and the oral mTOR inhibitor everolimus in patients with advanced pancreatic cancer.
Kordes S; Klümpen HJ; Weterman MJ; Schellens JH; Richel DJ; Wilmink JW
Cancer Chemother Pharmacol; 2015 Jun; 75(6):1135-41. PubMed ID: 25822310
[TBL] [Abstract][Full Text] [Related]
15. Phase Ib/II Trial of Ribociclib in Combination with Binimetinib in Patients with NRAS-mutant Melanoma.
Schuler M; Zimmer L; Kim KB; Sosman JA; Ascierto PA; Postow MA; De Vos FYFL; van Herpen CML; Carlino MS; Johnson DB; Berking C; Reddy MB; Harney AS; Berlin JD; Amaria RN
Clin Cancer Res; 2022 Jul; 28(14):3002-3010. PubMed ID: 35294522
[TBL] [Abstract][Full Text] [Related]
16. Phase I study of the anti-IGF1R antibody cixutumumab with everolimus and octreotide in advanced well-differentiated neuroendocrine tumors.
Dasari A; Phan A; Gupta S; Rashid A; Yeung SC; Hess K; Chen H; Tarco E; Chen H; Wei C; Anh-Do K; Halperin D; Meric-Bernstam F; Yao J
Endocr Relat Cancer; 2015 Jun; 22(3):431-41. PubMed ID: 25900182
[TBL] [Abstract][Full Text] [Related]
17. Everolimus combined with R-CHOP-21 for new, untreated, diffuse large B-cell lymphoma (NCCTG 1085 [Alliance]): safety and efficacy results of a phase 1 and feasibility trial.
Johnston PB; LaPlant B; McPhail E; Habermann TM; Inwards DJ; Micallef IN; Colgan JP; Nowakowski GS; Ansell SM; Witzig TE
Lancet Haematol; 2016 Jul; 3(7):e309-16. PubMed ID: 27374464
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety in older patient subsets in studies of endocrine monotherapy versus combination therapy in patients with HR+/HER2- advanced breast cancer: a review.
Freedman RA; Tolaney SM
Breast Cancer Res Treat; 2018 Feb; 167(3):607-614. PubMed ID: 29103175
[TBL] [Abstract][Full Text] [Related]
19. The Novel Cyclin-Dependent Kinase 4/6 Inhibitor Ribociclib (LEE011) Alone and in Dual-Targeting Approaches Demonstrates Antitumoral Efficacy in Neuroendocrine Tumors in vitro.
Aristizabal Prada ET; Nölting S; Spoettl G; Maurer J; Auernhammer CJ
Neuroendocrinology; 2018; 106(1):58-73. PubMed ID: 28226315
[TBL] [Abstract][Full Text] [Related]
20. Predictors of ribociclib-mediated antitumour effects in native and sorafenib-resistant human hepatocellular carcinoma cells.
Reiter FP; Denk G; Ziesch A; Ofner A; Wimmer R; Hohenester S; Schiergens TS; Spampatti M; Ye L; Itzel T; Munker S; Teufel A; Gerbes AL; Mayerle J; De Toni EN
Cell Oncol (Dordr); 2019 Oct; 42(5):705-715. PubMed ID: 31250364
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
